Now I have a thorough understanding of the paper. Let me synthesize the final review.

## Summary

MAESTRO proposes a self-supervised set representation learning architecture for cytometry data that combines masked autoencoding with self-distillation (DINO/iBOT-style) on top of a Set Transformer backbone. The key claims are: (1) it can handle sets of hundreds of thousands of elements (up to ~1.4M cells), which prior set methods cannot; (2) it produces sample-level embeddings that outperform existing approaches on diagnosis, age, sex, and cell-type distribution retrieval tasks; and (3) it introduces Non-Random Block Masking (NRBM) as a novel masking strategy. The paper targets a practically important problem — clinical cytometry lacks unsupervised methods that produce whole-sample immune profiles.

## Strengths

- **Scalability to very large sets**: MAESTRO successfully processes sets with up to ~1.4 million cells per sample, a regime where baselines like Deep Sets and Set Transformer require subsampling to 10,000 cells (Section 4.1, 4.4). This is a genuine practical advance for cytometry analysis, where samples routinely contain hundreds of thousands of cells.

- **Formal guarantees of permutation invariance/equivariance**: The paper provides theorems (1–4) proving that each attention block (MHA, ISAB, PMA, SAB) respects the required permutation properties, establishing a principled foundation for set representation learning.

- **Ablation confirms necessity of core components**: Table 1 demonstrates that removing either masked modeling or self-distillation substantially degrades downstream performance, providing empirical evidence that these design choices are individually important.

- **Comprehensive evaluation across multiple tasks**: The paper evaluates on both global (diagnosis, age, sex) and local (cell-type distribution retrieval) tasks, giving a more complete picture of representation quality than a single benchmark would.

## Weaknesses

### Major

- **Baseline training procedure is unspecified, making the main comparison difficult to interpret**: The paper describes Deep Sets and Set Transformer as "supervised approaches" in the Related Work section, but never clarifies how these baselines were trained for the experiments (Section 4.4). Were they trained from scratch on cytometry data with labels? Pre-trained on other data? Used in a self-supervised manner? If they were trained with labels on the same tasks used for linear probing, the comparison against self-supervised MAESTRO would not be apples-to-apples. Without this information, the reader cannot determine whether the reported outperformance reflects architectural superiority or a difference in training protocol. This is the single most consequential omission in the paper, as it directly affects the credibility of the central quantitative claims (Figures 4, 5).

- **NRBM novelty is not properly isolated**: The core methodological novelty advertised is Non-Random Block Masking. Yet the ablation study (Table 1) compares full MAESTRO against variants that remove "masked modelling" *entirely* — not against a version with standard *random* masking at the same mask ratio. It is therefore impossible to tell whether NRBM provides any benefit over the well-established MAE-style random masking. The contribution could collapse to "Set Transformer + MAE + DINO/iBOT" with no added value from the NRBM component. This is a significant gap for a paper that claims methodological novelty.

- **Insufficient dataset characterization**: The paper reports cell counts per sample (11,829–1,386,520) but omits: total number of samples, number and names of diagnostic classes, class balance, and how data was split for pre-training vs. linear probing. The paper mentions "a large cohort of cytometry samples" and that metadata came from "primary clinician teams for each study" (Section 4.1), but gives no concrete information about the evaluation setup. This makes it difficult to assess task difficulty or the validity of the reported metrics.

### Minor

- **No uncertainty quantification**: All metrics (accuracy, AUC, F1, MAE, R²) are reported as single numbers without confidence intervals, error bars, or significance tests. Given that baselines use random subsampling of 10,000 cells (introducing stochasticity), and given modest sample sizes typical of clinical studies, the reader has no way to assess whether the reported improvements are statistically meaningful.

- **Key architectural hyperparameters unspecified**: The number of inducing points *m* for ISAB — which directly controls the complexity/quality trade-off and is central to the scalability claims — is never stated or discussed. The mask ratio ρ is mentioned in Algorithm 1 but its actual value in experiments is not reported.

- **Reconstruction loss function not specified**: The paper uses masked reconstruction as a training objective (Section 3.2, Figure 2) but never states the loss function (MSE? cosine? cross-entropy?). The qualitative UMAP visualization of reconstruction (Figure 2) is insufficient; quantitative reconstruction error is not reported.

- **Manual gating baseline representation not explained**: For linear probing (Figure 4), manual gating is listed as a baseline, but the paper does not specify what representation is extracted from manual gating for use as features (cell-type proportions? gating thresholds?). This makes the baseline implementation unclear.

### Trivial

- **Radar plot in Figure 5(b)**: The caption states "As we move away from the center the MAE gets higher," but radial plots conventionally show higher values further from the center, which is intuitive. The caption's clarification suggests the presentation may be non-standard; consider redrawing for clarity.

## Nice-to-Haves

- Add a variant with standard random masking (same mask ratio) to isolate the benefit of NRBM over random.
- Include a controlled experiment where MAESTRO and baselines are evaluated with matched input sizes (e.g., both using 10K cells) to disentangle architectural benefit from data quantity advantage.
- Report metrics with confidence intervals (e.g., bootstrap or cross-validation).
- Disclose training hyperparameters (learning rate, batch size, epochs, EMA momentum) — likely present in a stripped appendix, but should be in the main text given their centrality to reproducibility.

## Removed Points

The following points from the reviews were identified as invalid, factually wrong, or inapplicable, and are listed here for traceability:

1. **"Information advantage" of full set over 10K subset is an unfair comparison** — This is a feature of the method, not a flaw. MAESTRO's scalability advantage over baselines IS the contribution. The critic frames a core strength as a weakness. (However, a controlled experiment matching input sizes would still be informative as a Nice-to-Have.)

2. **Hyperparameter details (lr, batch size, epochs, etc.) are missing** — The paper references implementation details in Appendix F.5, which was stripped by the parser. Per the meta-reviewer instructions, criticisms of missing appendix content are removed.

3. **"First attention-based self-supervised set representation model" claim needs more discussion** — This is a request for expanded related work, which the meta-reviewer instructions disallow (no external verification of missing citations).

4. **Strength Finder strengths about "outperforming all baselines"** — These are conditional on resolving the baseline training procedure concern, but are kept in spirit as reflecting the paper's claims.

## Novel Insights

The key gap this review reveals is a mismatch: the paper claims both a *methodological* novelty (NRBM) and an *application-domain* novelty (first self-supervised set representation for cytometry), but the experimental design isolates neither convincingly. NRBM is uncompared against random masking, so the methodological novelty is untested. The baselines' training procedure is unstated, so the performance advantage could be an artifact of asymmetric supervision rather than genuine representation quality. The paper would be much stronger if it chose one narrative — either "we introduce a novel masking strategy and ablate it properly" or "we apply existing SSL techniques to a new domain with practical benefits" — and designed experiments around that single claim rather than bundling both with incomplete controls.

## Suggestions

1. In the rebuttal or revision, explicitly state how each baseline was trained (supervised or self-supervised; pre-trained or from scratch; which loss function) and include this in the main paper.
2. Add a variant with standard random masking to the ablation to isolate NRBM's contribution.
3. Provide dataset statistics: number of samples per diagnosis class, train/val/test split sizes, and class balance.
4. Add confidence intervals or standard deviations (over multiple seeds or cross-validation folds) to all quantitative results.
5. Specify the reconstruction loss function and the value of *m* (inducing points) used in experiments.

## Score and Decision

The paper addresses a practically important problem and demonstrates genuine scalability (up to 1.4M cells) that prior methods cannot match. The theoretical grounding for permutation invariance is solid. However, the evaluation has two structural gaps: (1) the baseline training procedure is unspecified, making the central comparison uninterpretable, and (2) the claimed novelty (NRBM) is not isolated against random masking. These are major weaknesses that prevent the paper from convincingly supporting its contributions. The paper is not fatally flawed — the scalability and self-supervised framing are contributions regardless — but the experimental evidence as presented is insufficient to justify the strong claims.

MY FINAL SCORE: <pineapple>5.0</pineapple>
MY FINAL DECISION: <orange>Reject</orange>